Shares in Morphosys AG surged by more than 17 percent during trading last week on news of a deal with Celgene Corp. for its anti-CD38 multiple myeloma antibody MOR202, worth an immediate €127 million (US$165.5 million) and which could be worth up to €628 million in total. Read More
LONDON – The prospect of being able to control the activity of drugs in body tissues by illuminating them has moved a step closer, with the discovery of a way of using light to activate peptides inside a cell. Read More
LONDON – Heptares Ltd. has raised $21 million in a Series B funding co-led by the Stanley Family Foundation, one of the leading foundations investing in neuroscience diseases. Read More
Complix NV raised €12 million (US$15.6 million) in a Series B round to fund development of small-protein therapeutics based on its alphabody scaffold platform. Read More
LONDON – The UK government has given the go-ahead to mitochondrial replacement in in vitro fertilization, a technology that would result in children being born with DNA from three people. Read More
SHANGHAI – Looking to create synergies between its own expertise and growing pool of small and medium biotech ventures in China, Boehringer Ingelheim Pharmaceuticals GmbH (BI) plans to build the first international biopharma contract manufacturing facility (CMO) in the country with mammalian cell technology. Read More
• Kamada Ltd., of Ness Ziona, Israel, said the Israeli Ministry of Health (IMOH) has completed a successful good manufacturing practice (GMP) audit of the company's manufacturing facility in Beit Kama, Israel. Read More
